RPG Life Sciences Limited (BOM:532983)
India · Delayed Price · Currency is INR 2,402.25
+125.85 (5.53%)
At close: Oct 20, 2025
RPG Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 6,664 | 6,534 | 5,821 | 5,128 | 4,402 | 3,891 | Upgrade | |
Revenue Growth (YoY) | 7.78% | 12.26% | 13.50% | 16.50% | 13.11% | 3.61% | Upgrade |
Cost of Revenue | 2,367 | 2,192 | 1,893 | 1,758 | 1,469 | 1,356 | Upgrade |
Gross Profit | 4,297 | 4,342 | 3,928 | 3,370 | 2,932 | 2,535 | Upgrade |
Selling, General & Admin | 1,563 | 1,523 | 1,542 | 1,346 | 1,153 | 1,055 | Upgrade |
Other Operating Expenses | 1,232 | 1,211 | 1,104 | 988.4 | 915.5 | 779.5 | Upgrade |
Operating Expenses | 3,006 | 2,948 | 2,817 | 2,489 | 2,225 | 1,999 | Upgrade |
Operating Income | 1,291 | 1,394 | 1,111 | 881 | 707.4 | 536.6 | Upgrade |
Interest Expense | -5.5 | -6.2 | -4.5 | -3.1 | -5.2 | -7.9 | Upgrade |
Interest & Investment Income | 32.1 | 32.1 | 14.2 | 27.3 | 13.3 | 3.2 | Upgrade |
Currency Exchange Gain (Loss) | 1.6 | 1.6 | 0.1 | 5 | 7.3 | 4 | Upgrade |
Other Non Operating Income (Expenses) | 102.1 | 47.5 | 47.2 | 14.4 | - | - | Upgrade |
EBT Excluding Unusual Items | 1,421 | 1,469 | 1,168 | 924.6 | 722.8 | 535.9 | Upgrade |
Gain (Loss) on Sale of Investments | 12 | 12 | 0.1 | - | 8.9 | - | Upgrade |
Gain (Loss) on Sale of Assets | 22.1 | 22.1 | 10.5 | -7.8 | - | -0.1 | Upgrade |
Other Unusual Items | 1,211 | 826 | - | - | - | - | Upgrade |
Pretax Income | 2,667 | 2,329 | 1,178 | 916.8 | 731.7 | 535.8 | Upgrade |
Income Tax Expense | 512.5 | 496.4 | 301.8 | 240.4 | 216.9 | 135.8 | Upgrade |
Earnings From Continuing Operations | 2,154 | 1,832 | 876.6 | 676.4 | 514.8 | 400 | Upgrade |
Net Income | 2,154 | 1,832 | 876.6 | 676.4 | 514.8 | 400 | Upgrade |
Net Income to Common | 2,154 | 1,832 | 876.6 | 676.4 | 514.8 | 400 | Upgrade |
Net Income Growth | 204.87% | 109.03% | 29.60% | 31.39% | 28.70% | 37.88% | Upgrade |
Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade |
Shares Change (YoY) | -0.01% | - | - | - | - | - | Upgrade |
EPS (Basic) | 130.25 | 110.79 | 53.00 | 40.90 | 31.13 | 24.19 | Upgrade |
EPS (Diluted) | 130.25 | 110.79 | 53.00 | 40.90 | 31.13 | 24.19 | Upgrade |
EPS Growth | 204.88% | 109.03% | 29.60% | 31.39% | 28.70% | 37.88% | Upgrade |
Free Cash Flow | -10 | 418.3 | 251.3 | 580.9 | 408 | 497.6 | Upgrade |
Free Cash Flow Per Share | -0.60 | 25.29 | 15.19 | 35.12 | 24.67 | 30.09 | Upgrade |
Dividend Per Share | - | 20.000 | 16.000 | 12.000 | 9.600 | 7.200 | Upgrade |
Dividend Growth | - | 25.00% | 33.33% | 25.00% | 33.33% | 80.00% | Upgrade |
Gross Margin | 64.49% | 66.45% | 67.48% | 65.72% | 66.62% | 65.15% | Upgrade |
Operating Margin | 19.37% | 21.33% | 19.08% | 17.18% | 16.07% | 13.79% | Upgrade |
Profit Margin | 32.33% | 28.04% | 15.06% | 13.19% | 11.70% | 10.28% | Upgrade |
Free Cash Flow Margin | -0.15% | 6.40% | 4.32% | 11.33% | 9.27% | 12.79% | Upgrade |
EBITDA | 1,497 | 1,602 | 1,271 | 1,024 | 846.2 | 683.5 | Upgrade |
EBITDA Margin | 22.46% | 24.51% | 21.84% | 19.97% | 19.23% | 17.56% | Upgrade |
D&A For EBITDA | 205.4 | 207.8 | 160.6 | 143 | 138.8 | 146.9 | Upgrade |
EBIT | 1,291 | 1,394 | 1,111 | 881 | 707.4 | 536.6 | Upgrade |
EBIT Margin | 19.37% | 21.33% | 19.08% | 17.18% | 16.07% | 13.79% | Upgrade |
Effective Tax Rate | 19.22% | 21.32% | 25.61% | 26.22% | 29.64% | 25.35% | Upgrade |
Revenue as Reported | 6,845 | 6,661 | 5,893 | 5,176 | 4,432 | 3,901 | Upgrade |
Advertising Expenses | - | 250.4 | 213 | 168.1 | 146.6 | 101 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.